January 5, 2022

The COVID-19 pandemic had had a considerable impact on biotech and pharma services outsourcing, as companies struggled to overcome supply chain issues in production, manufacturing and talent. This held true not only from an R&D perspective, but throughout the product lifecycle as biopharma continued to bring therapies to an evolving market.

Michael Jimmink, Vice President, FSP 360 and Jim Reidy, Vice President, Deployment Solutions from Syneos Health discuss ways to navigate business continuity through strategic outsourcing, including why, how and when to consider outsourcing solutions, as well as ways to utilize fit-for-purpose resourcing while maintaining strategic oversight.

For more on the topics covered in this episode, be sure to check out:

2022 Health Trends: Insights for Industry Change Agents

Are You Assembling the Right Team for Commercial Success?

FSP 360: A Flexible, Customizable Solution for Your Outsourcing Needs

Outsourcing R&D in Today’s Market

Scroll to Page Bottom Form 
Enabled